Publication
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (7)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 7
- cancerOvarian Serous Adenocarcinomacivic_curation1.00
- drugMitogen-Activated Protein Kinase Kinase Inhibitorcivic_curation1.00
- drugSelumetinibcivic_curation1.00
- geneCUL1civic_curation1.00
- geneMAP2K1civic_curation1.00
- variantCUL1 Fusioncivic_curation1.00
- variantMAP2K1 Q56_V60delcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26324360
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| CUL1 Fusion1 | ||||||||
| Mitogen-Activated Protein Kinase Kinase Inhibitor | Ovarian Serous AdenocarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1662One patient with low-grade serous ovarian cancer had an in-frame fusion between the BRAF kinase domain and CUL1 identified by panel sequencing (MSK-IMPACT), with expression confirmed by whole-transcri… (full text at CIViC) PMID 26324360 · Grisham et al., 2015 · Open in CIViC | civic |
| MAP2K1 Q56_V60del1 | ||||||||
| Selumetinib | Ovarian Serous AdenocarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID1661Case report of a 51-year old patient with recurrent low-grade serous ovarian cancer. Selumetinib treatment in a phase-II trial led to a complete and durable response > 5 years. Sequencing (MSK-IMPACT … (full text at CIViC) PMID 26324360 · Grisham et al., 2015 · Open in CIViC | civic |